LLY

1,123.54

+3.6%↑

JNJ

231.47

+0.05%↑

ABBV

218.3

+1.32%↑

UNH

383.9

+0.44%↑

MRK

120.03

-0.68%↓

LLY

1,123.54

+3.6%↑

JNJ

231.47

+0.05%↑

ABBV

218.3

+1.32%↑

UNH

383.9

+0.44%↑

MRK

120.03

-0.68%↓

LLY

1,123.54

+3.6%↑

JNJ

231.47

+0.05%↑

ABBV

218.3

+1.32%↑

UNH

383.9

+0.44%↑

MRK

120.03

-0.68%↓

LLY

1,123.54

+3.6%↑

JNJ

231.47

+0.05%↑

ABBV

218.3

+1.32%↑

UNH

383.9

+0.44%↑

MRK

120.03

-0.68%↓

LLY

1,123.54

+3.6%↑

JNJ

231.47

+0.05%↑

ABBV

218.3

+1.32%↑

UNH

383.9

+0.44%↑

MRK

120.03

-0.68%↓

Home・Aktien・Illumina Inc

Illumina Inc

Open

BrancheGesundheitswesen

156.9 7.47

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

144.46

Max

156.65

Schlüsselkennzahlen
By Trading Economics
Einkommen	-200M 134M
Verkäufe	-68M 1.1B
KGV Branchendurchschnitt	26.256 50.102
EPS	1.15
Gewinnspanne	12.282
Angestellte	8,600
EBITDA	-144M 301M

Empfehlungen
By TipRanks
Empfehlungen	Neutral
12-Monats-Prognose	-2.62% downside

Dividenden
By Dow Jones
Nächstes Ergebnis	30. Juli 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	2.3B 22B
Vorheriger Eröffnungskurs	149.43
Vorheriger Schlusskurs	156.9

Nachrichtenstimmung

By Acuity

42%

58%

103 / 344 Ranking in Healthcare

Illumina Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Illumina Inc Prognose

Kursziel

By TipRanks

-2.62% Nachteil

12-Monats-Prognose

Durchschnitt 141.42 USD -2.62%

Hoch 170 USD

Tief 95 USD

Basierend auf 12 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Illumina Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

12 ratings

Buy

Halten

Sell

Basierend auf 12 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Illumina Inc – Dist abgegeben haben.

Stimmung

By Acuity

103 / 344 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Illumina Inc

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.